# TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers

> **NCT01288677** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 54 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** TMC649128

## Key facts

- **NCT ID:** NCT01288677
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288677, "TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01288677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*